α-2b干扰素联合恩替卡韦在慢性乙型肝炎患者中的应用效果及对T淋巴细胞百分比的影响研究

Effect of alpha-2b interferon and entecavir for patients with chronic hepatitis B and its influence on percentage of T lymphocytes

目的分析α-2b干扰素联合恩替卡韦在慢性乙型肝炎患者中的应用效果及对T淋巴细胞百分比的影响。方法选取2017年1月至2019年1月本院收治的慢性乙型肝炎患者68例,随机分为两组,各34例。对照组给予恩替卡韦治疗,研究组给予α-2b干扰素联合恩替卡韦治疗。观察分析两组患者T淋巴细胞指标变化情况、不良反应发生率以及HBV-DNA不可检测率、HBeAg转换率和HBeAg阴转率变化情况。结果研究组HBV-DNA不可检测率、HBeAg转换率、HBeAg阴转率分别为50.0%(17/34)、67.6%(23/34)、61.8%(21/34),均高于对照组23.5%(8/34)、41.2%(14/34)、35.3%(12/34),差异均有统计学意义(均P<0.05);治疗前,两组患者CD4+、CD8+、CD4+/CD8+水平比较,差异均无统计学意义(均P>0.05);治疗后,研究组CD4+、CD4+/CD8+水平分别为(47.2±9.8)%、(2.9±1.3),均高于对照组,CD8+水平为(23.4±5.6)%,低于对照组,差异均有统计学意义(均P<0.05);研究组不良反应发生率为11.8%(4/34),低于对照组35.3%(12/34),差异有统计学意义(P<0.05)。结论慢性乙型肝炎患者应用α-2b干扰素与恩替卡韦联合治疗效果较为理想,可有效减轻患者不适感,改善炎性因子水平,临床可推广使用。

Objective To analyze the effect of alpha-2b interferon and entecavir for patients with chronic hepatitis B and its influence on percentage of T lymphocytes.Methods 68 patients with chronic hepatitis B admitted to our hospital from January,2017 to January,2019 were randomly divided into a study group and a control group,with 34 cases in each group.The control group was treated with entecavir,and the study group with alpha-2b interferon and entecavir.The changes of T lymphocyte indicators,the incidences of adverse reactions,the undetectable rates of HBV DNA,the conversion rates of HBeAg,and the negative conversion rates of HBeAg in the two groups were observed and analyzed.Results The HBV DNA undetectable rate,HBeAg conversion rate,and HBeAg negative conversion rate were higher in the study group than in the control group50.0%(17/34)vs.23.5%(8/34),67.6%(23/34)vs.41.2%(14/34),61.8%(21/34)vs.35.3%(12/34);all P<0.05.There were no statistical differences in the levels of CD4+,CD8+,and CD4+/CD8+between the two groups before the treatment(all P>0.05).The levels CD4+,CD8+,and CD4+/CD8+were(47.2±9.8)%,(23.4±5.6)%,and(2.9±1.3)in the study group,which were better than those in the control group(all P<0.05).The incidence of adverse reactions in the study group was lower than that in the control group[11.8%(4/34)vs.35.3%(12/34),P<0.05)].Conclusion The combination of alpha-interferon with entecavir for patients with chronic hepatitis B has an ideal therapeutic effect,and can effectively reduce the patients’discomfort and improve the levels of inflammatory factors.